SLC5A2 and chronic kidney disease: In heart failure as well as in chronic kidney disease sodium-glucosecotransporter 2 (SGLT2) inhibitors have changed the landscape of medical therapy.Originally developed for use in diabetes, an unforeseen cardiovascular benefitextended SGLT2 inhibitor use from antihyperglycemic agents to cardiovascular andrenal risk modifying agents.